Filtered By:
Source: The American Journal of Cardiology
Condition: Ischemic Stroke
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 182 results found since Jan 2013.
Significance of an Abnormal Ankle-Brachial Index in Patients With Established Coronary Artery Disease With and Without Associated Diabetes Mellitus
In conclusion, in patients with stable CAD, an abnormal ABI confers an incremental risk of MACE in addition to DM and traditional CV risk factors.
Source: The American Journal of Cardiology - February 3, 2014 Category: Cardiology Authors: Subhash Banerjee, Ariel Vinas, Atif Mohammad, Omar Hadidi, Rahul Thomas, Karan Sarode, Avantika Banerjee, Puja Garg, Rick A. Weideman, Bertis B. Little, Emmanouil S. Brilakis Tags: Coronary Artery Disease Source Type: research
Safety of Short-Term Use of Dabigatran or Rivaroxaban for Direct-Current Cardioversion in Patients With Atrial Fibrillation and Atrial Flutter
In conclusion, the use of short-term dabigatran or rivaroxaban therapy for DCCV of AF appears safe.
Source: The American Journal of Cardiology - February 3, 2014 Category: Cardiology Authors: Ajay Yadlapati, Christopher Groh, Rod Passman Tags: Arrhythmias and Conduction Disturbances Source Type: research
Atrial Fibrillation and Heart Failure: A Bad Combination
Atrial fibrillation (AF) and heart failure (HF) commonly coexist and share similar risk factors such as hypertension, increasing age, valvular heart disease, previous ischemic cardiac event, and diabetes mellitus. Individually, AF and HF increase the risk of stroke and death, and the synergistic combination of AF and HF creates a prothrombotic state that results in worse stroke morbidity and mortality than the mere presence of either condition separately.
Source: The American Journal of Cardiology - January 17, 2014 Category: Cardiology Authors: Yee C. Lau, Deirdre A. Lane, Gregory Y.H. Lip Tags: Heart Failure Source Type: research
Meta-Analysis of Risk of Stroke or Transient Ischemic Attack With Dabigatran for Atrial Fibrillation Ablation
In conclusion, periprocedural use of dabigatran for AF ablation was related to a higher risk of thromboembolic complications including stroke and transient ischemic attack.
Source: The American Journal of Cardiology - January 16, 2014 Category: Cardiology Authors: Partha Sardar, Ramez Nairooz, Saurav Chatterjee, Jørn Wetterslev, Joydeep Ghosh, Wilbert S. Aronow Tags: Arrhythmias and Conduction Disturbances Source Type: research
Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)
In conclusion, most TRACER participants were treated with low-dose ASA, although a high dose was common in North America. High-dose participants tended to have higher rates of ischemic and bleeding outcomes. Although formal statistical testing did not reveal heterogeneity in vorapaxar's effect across dose subgroups, consistent trends support use of low-dose ASA with other antiplatelet therapies.
Source: The American Journal of Cardiology - December 26, 2013 Category: Cardiology Authors: Kenneth W. Mahaffey, Zhen Huang, Lars Wallentin, Robert F. Storey, Lisa K. Jennings, Pierluigi Tricoci, Harvey D. White, Paul W. Armstrong, Philip E. Aylward, David J. Moliterno, Frans Van de Werf, Edmond Chen, Sergio Leonardi, Tyrus Rorick, Claes Held, J Tags: Coronary Artery Disease Source Type: research
Impact of Gender on the Prognosis of Patients With Nonvalvular Atrial Fibrillation
Treatment guidelines for atrial fibrillation (AF) used in Western countries describe female gender as a risk factor for thromboembolic events in patients with nonvalvular AF (NVAF). The present study aimed to determine the impact of gender on prognosis of Japanese patients with NVAF. A subanalysis of 7,406 patients with NVAF (mean age 70 years) who were followed-up prospectively for 2 years was performed using data from the J-RHYTHM registry. The primary end points were thromboembolic events, major hemorrhaging, total mortality, and cardiovascular mortality. Compared with male subjects (n = 5,241), female subjects (n =...
Source: The American Journal of Cardiology - December 26, 2013 Category: Cardiology Authors: Hiroshi Inoue, Hirotsugu Atarashi, Ken Okumura, Takeshi Yamashita, Hideki Origasa, Naoko Kumagai, Masayuki Sakurai, Yuichiro Kawamura, Isao Kubota, Kazuo Matsumoto, Yoshiaki Kaneko, Satoshi Ogawa, Yoshifusa Aizawa, Masaomi Chinushi, Itsuo Kodama, Eiichi W Tags: Arrhythmias and Conduction Disturbances Source Type: research
Impact of Increased Orifice Size and Decreased Flow Velocity of Left Atrial Appendage on Stroke in Nonvalvular Atrial Fibrillation
This study investigated whether a larger LAA orifice is related to decreased LAA flow velocity and stroke in nonvalvular AF. The dimension, morphology, and flow velocity of LAA were compared in patients with nonvalvular AF with (stroke group, n = 67, mean age 66 ± 9 years) and without ischemic stroke (no-stroke group, n = 151, mean age 56 ± 10 years). Compared with no-stroke group, the stroke group had larger LA dimension (4.7 ± 0.8 vs 4.2 ± 0.6 cm, p
Source: The American Journal of Cardiology - December 26, 2013 Category: Cardiology Authors: Jung Myung Lee, Jaemin Shim, Jae-Sun Uhm, Young Jin Kim, Hye-Jeong Lee, Hui-Nam Pak, Moon-Hyoung Lee, Boyoung Joung Tags: Arrhythmias and Conduction Disturbances Source Type: research
Prevalence of and Risk Factors for Silent Ischemic Stroke in Patients With Atrial Fibrillation as Determined by Brain Magnetic Resonance Imaging
Varied silent ischemic stroke (SS) prevalence occurs in patients with atrial fibrillation (AF). Stroke history is worth 2 points in the CHADS2 scoring system. An unknown proportion of patients with AF with a CHADS2 score of 0 or 1 have been undertreated for stroke prevention. We investigated SS risk factors using magnetic resonance imaging and estimated SS impact on clinical outcomes in patients with AF. We analyzed a total of 1,200 patients (400 with AF and 800 with sinus rhythm) who had brain magnetic resonance imaging performed for routine health checkups. Clinical outcomes including symptomatic stroke, dementia, and co...
Source: The American Journal of Cardiology - November 25, 2013 Category: Cardiology Authors: Myung-jin Cha, Hyo Eun Park, Min-ho Lee, Youngjin Cho, Eue-keun Choi, Seil Oh Tags: Arrhythmias and Conduction Disturbances Source Type: research
Usefulness of a Combination of Monocyte Chemoattractant Protein-1, Galectin-3, and N-Terminal Probrain Natriuretic Peptide to Predict Cardiovascular Events in Patients With Coronary Artery Disease
Patients with coronary artery disease may develop not only ischemic events but also heart failure and death due to previous myocardial damage. The purpose of this study was to test the prognostic value of a panel of plasma biomarkers related to vascular (monocyte chemoattractant protein-1 [MCP-1] and soluble tumor necrosis factor–like weak inducer of apoptosis) and myocardial damage (galectin-3, N-terminal fragment of brain natriuretic peptide [NT-proBNP], and neutrophil gelatinase–associated lipocalin) in 706 patients with chronic coronary artery disease followed for 2.2 ± 0.99 years. Secondary outcomes were the inc...
Source: The American Journal of Cardiology - November 11, 2013 Category: Cardiology Authors: José Tuñón, Luis Blanco-Colio, Carmen Cristóbal, Nieves TarÃn, Javier Higueras, Ana Huelmos, JoaquÃn Alonso, Jesús Egido, Dolores Asensio, Óscar Lorenzo, Ignacio MahÃllo-Fernández, Fernando RodrÃguez-Artalejo, Jerónimo Farré, José Luis Martà Tags: Coronary Artery Disease Source Type: research
Adverse Cardiovascular, Cerebrovascular, and Peripheral Vascular Effects of Marijuana Inhalation: What Cardiologists Need to Know
In conclusion, the potential for increased use of marijuana in the changing legal landscape suggests the need for the community to intensify research regarding the safety of marijuana use and for cardiologists to maintain an awareness of the potential for adverse effects.
Source: The American Journal of Cardiology - October 30, 2013 Category: Cardiology Authors: Grace Thomas, Robert A. Kloner, Shereif Rezkalla Tags: Review Source Type: research
Association Between Intraprocedural Thrombotic Events and Adverse Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (a Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction HORIZONS-AMI Substudy)
The present study sought to determine the extent to which adverse angiographic events encountered during percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI) are associated with adverse clinical outcomes. Patients with STEMI represent a cohort at particularly high risk of intraprocedural thrombotic events (IPTEs). The overall frequency and implications of IPTEs occurring in patients with STEMI have not been systematically quantified in previous studies. A total of 3,163 patients undergoing primary percutaneous coronary intervention with stent implantation for STEMI in the Harmonizing Ou...
Source: The American Journal of Cardiology - October 28, 2013 Category: Cardiology Authors: Ajay J. Kirtane, Prabhdeep Sandhu, Roxana Mehran, Margaret McEntegart, Ecaterina Cristea, Sorin J. Brener, Ke Xu, Martin Fahy, Philippe Généreux, Jeffrey D. Wessler, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research
Comparison of Outcomes for Patients ≥75 Years of Age Treated With Pre-Hospital Reduced-Dose Fibrinolysis Followed by Percutaneous Coronary Intervention Versus Percutaneous Coronary Intervention Alone for Treatment of ST-Elevation Myocardial Infarction
A coordinated system of care for patients with ST-segment elevation myocardial infarctions that includes prehospital administration of reduced-dose fibrinolytic agents coupled with urgent percutaneous coronary intervention (PCI), termed FAST-PCI, has been shown to be at least as effective as primary PCI (PPCI) alone. However, this reduced-dose fibrinolytic strategy could be associated with increased bleeding risk, especially in elderly patients. The purpose of this study was to examine 30-day outcomes in patients aged ≥75 years with ST-segment elevation myocardial infarctions treated with either strategy. Data from 120 p...
Source: The American Journal of Cardiology - October 28, 2013 Category: Cardiology Authors: Amirreza Solhpour, Kay-Won Chang, Prakash Balan, Chunyan Cai, Stefano Sdringola, Ali E. Denktas, Richard W. Smalling, H. Vernon Anderson Tags: Coronary Artery Disease Source Type: research
Comparison of Statin Alone Versus Bezafibrate and Statin Combination in Patients With Diabetes Mellitus and Acute Coronary Syndrome
In conclusion, a significantly lower risk for 30-day MACEs was observed in statin-treated patients with DM who also received bezafibrate after ACS. Signals regarding improvement of 30-day rehospitalization and 1-year mortality rates emerged as well.
Source: The American Journal of Cardiology - October 24, 2013 Category: Cardiology Authors: Robert Klempfner, Ilan Goldenberg, Enrique Z. Fisman, Shlomi Matetzky, Uri Amit, Joseph Shemesh, Alexander Tenenbaum Tags: Coronary Artery Disease Source Type: research
Applying Antithrombotic Therapies to Improve Outcomes in Patients With Atrial Fibrillation
Abstract: Approximately 15% to 25% or 75,000 ischemic strokes are attributed to atrial fibrillation annually within the United States. Atrial fibrillation is the most frequently diagnosed cardiac arrhythmia and affects more than 2.66 million Americans. Moreover, atrial fibrillation is associated with a 1.5 to 1.9-fold higher risk of death due to its strong correlation with thromboembolic events. Because of the attributed increased morbidity and mortality, challenges that concern identification of patients at risk for thromboembolic events from atrial fibrillation must be addressed. These challenges include compliance to pe...
Source: The American Journal of Cardiology - August 1, 2013 Category: Cardiology Authors: Chris Cannon, Michael D. Ezekowitz, Christopher Granger Tags: Multimedia Activities Source Type: research
Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP VerifyNow and Inhibition of Platelet Reactivity Study)
In conclusion, 1/3 of patients with acute coronary syndromes who underwent percutaneous coronary intervention and stenting showed high on-treatment RPR on bedside monitoring. They had a worse prognosis, but the level of platelet inhibition was not independently associated with the incidence of ischemic or bleeding events.
Source: The American Journal of Cardiology - June 7, 2013 Category: Cardiology Authors: Francesco Saia, Massimiliano Marino, Gianluca Campo, Marco Valgimigli, Paolo Guastaroba, Nevio Taglieri, Stefano Tondi, Antonio Manari, Vincenzo Guiducci, Pietro Sangiorgio, Elisabetta Varani, Paolo Magnavacchi, Rossana De Palma, Antonio Marzocchi Tags: Coronary Artery Disease Source Type: research
